This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Filter 4,243 trials Clear all
Filter by:

Hydroxychloroquine for Treatment of Non-Severe COVID-19

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Covid19
    Covid19
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Hydroxychloroquine tablets

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Hydroxychloroquine tablets

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Namboole COVID-19 treatment unit, Kampala, Uganda

Brief Summary

Currently there are no proven treatments for COVID-19 and current standard therapy is supportive care with oxygen supplementation and treatment of symptoms. Several re-purposed and new drugs have been investigated but none is conclusive for efficacy against COVID-19 .Both Hydroxychloroquine(HCQ) and Chloroquine(CQ) have demonstrated activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and have been investigated in small clinical trials with contradicting reports on their benefits or harm in treatment of COVID-19 .Several authors agree that the use of HCQ for treatment of COVID-19 needs to be assessed in large randomized controlled trials

Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Covid19
    Covid19
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: COMIRNATY

Eligibility
  • Ages: 18 to 60 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Drug: COMIRNATY

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Hospital Universitario de Cruces, Barakaldo, Vizkaia, Spain

Brief Summary

CombiVacS is a phase 2 randomized, adaptive trial developed to evaluate the immunogenicity of a dose of COMIRNATY after a previous single dose of VAXZEVRIA. A stratification will be made based on the following factors: study site, sex and age. This protocol allows to test the immunogenicity and safety of a heterologous vaccination strategy after a previous single dose of VAXZEVRIA.

Combined Treatment With CO2 Laser and Isotretinoin for Acne Scars

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Acne Vulgaris
    Acne Vulgaris
  • Phase Phase 2
    Phase 2
INTERVENTION

Combination Product: Isotretinoin and CO2 laser, Device: Co2 laser

Eligibility
  • Ages: 15 to 60 Years (Child, Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
INTERVENTION

Combination Product: Isotretinoin and CO2 laser, Device: Co2 laser

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Tel Aviv sourasky medical center, Tel Aviv, Israel

Brief Summary

Isotretinoin is an FDA-approved vitamin A metabolite for the treatment of severe acne; acne that does not respond to other treatments and has a tendency to cause scarring. Ablative laser treatment is another effective treatment against acne scarring. We believe that the combination of CO2 ablative laser treatment with oral isotretinoin for the treatment of scarring is not only safer but also more effective and leads to much more successful cosmetic results.

A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Parkinson Disease
    Parkinson Disease
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: KDT-3594

Eligibility
  • Ages: 20 to 79 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: KDT-3594

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Research Site, Multiple Locations, Japan

Brief Summary

Objective of this study is to investigate the safety, pharmacokinetics and efficacy of KDT-3594 in patients with early Parkinson's disease without a concomitant medication of L-dopa.

NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Ataxia Telangiectasia
    Ataxia Telangiectasia
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Nicotinamide ribonucleoside

Eligibility
  • Ages: 3 Years and older (Child, Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Nicotinamide ribonucleoside

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Hilde Loge Nilsen, Lørenskog, Norway

Brief Summary

The study investigates the effect of dietary supplementation of nicotinamide ribonucleoside (NR) in children with ataxia telangiectasia (AT), with main focus on neurological symptoms.

Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Retinitis Pigmentosa
    Retinitis Pigmentosa
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Prescribe N-acetylcysteine tablets, Drug: Prescribe placebo tablets

Eligibility
  • Ages: 18 to 40 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Prescribe N-acetylcysteine tablets, Drug: Prescribe placebo tablets

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Ophthalmic Research Center, Tehran, Iran, Islamic Republic of

Brief Summary

Retinitis pigmentosa (RP) is an inherited retinal disease with great heterogeneity. RP comprises a large group of genetic disorders causing progressive loss of vision. Despite many suggested treatments, there is actually no effective therapy for most types of RP at present. Mutations that cause RP initially lead to rod cell death. After rod photoreceptors' death, cone photoreceptors also gradually die. There are several hypotheses as to why mutation-induced rod photoreceptor cell death invariably leads to gradual dysfunction and death of cone photoreceptors resulting in severe visual acuity loss and blindness. Rods constitute 95 percent of cells in the outer retina. As they degenerate, oxygen consumption is reduced and the level of tissue oxygen markedly increases. After rods degeneration, several markers of oxidative damage appear in cones. This oxidative stress over time may lead to cone dysfunction and death. Antioxidants reduce markers of oxidative damage and promote cone function and survival. In RP, cone death occurs as a result of the death of rods, rather than as the result of the pathogenic mutations and therefore treatment with antioxidants may have the potential to be applied to all patients with RP irrespective of the disease-causing mutation. N-acetylcysteine is a derivative of L cysteine that plays a role in the biosynthesis of glutathione and neutralizes reactive oxygen species. It also has a direct antioxidant activity via its reactive sulfhydryl agent. Its systemic use shows an acceptable safety profile. It has been shown that the use of systemic N-acetylcysteine provides significant intraocular concentration and antioxidant activity that may lead to the promotion of cone function and survival. In a recent phase 1 randomized clinical trial (RCT), it was revealed that oral N-acetylcysteine (NAC) was safe and well-tolerated in patients with moderately advanced RP and might improve sub-optimally functioning macular cones. The authors concluded that a randomized, placebo-controlled trial is needed to determine if oral NAC can provide long-term stabilization and/or improvement in visual function in patients with RP. In this phase 2 RCT, eligible patients with the diagnosis of moderately advanced RP are randomly divided into two groups; treatment group (N-acetylcysteine tablets) and controls (placebo). Each group will be treated for 6 months. In this study, we will investigate if the use of oral N- acetylcysteine as a potent antioxidant agent can slow down or reverse the disease process in RP patients with prior moderate loss of vision. It may potentially demonstrate a treatment modality regardless of the genetic type of RP. The primary outcome measure will be the stability or improvement of the best-corrected visual acuity (BCVA). The secondary outcome measures will be changes in color vision, electroretinogram, visual field, structural OCT indices after 6 months. The same parameters will be re-evaluated 3 months after discontinuation of treatment at month 9.

CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

  • Status Active, not recruiting
    Active, not recruiting
  • Condition CLL
    CLL
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: ibrutinib, venetoclax, obinutuzumab, Drug: ibrutinib, venetoclax

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: ibrutinib, venetoclax, obinutuzumab, Drug: ibrutinib, venetoclax

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

DK-Aalborg-AALBORGUH, Aalborg, Denmark

Brief Summary

A recent study showed that 6 cycles of obinutuzumab when given after at least 1 year of ibrutinib did result in MRD conversion in a significant proportion of patients (50%). The precise influence, timing and interplay of venetoclax, ibrutinib and obinutuzumab on clearance of CLL cells in different compartments (PB, BM, LN), and achievement of uMRD and complete remission (CR) are not well known. Therefore, the investigators set out a study to evaluate whether patients who are not in CR or who have detectable MRD after 12 months of combination treatment with ibrutinib and venetoclax (15 months total treatment including three months ibrutinib lead-in) could be converted into uMRD CR with an additional 6 cycles obinutuzumab in combination with ibrutinib.

A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Triple-negative Breast Cancer
    Triple-negative Breast Cancer
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Drug: HX008+Cisplatin+Gemcitabine

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: HX008+Cisplatin+Gemcitabine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Brief Summary

HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. In this study, the safety and preliminary efficacy of HX008+cisplatin+gemcitabine for the treatment of patients with metastatic triple-negative breast cancer will be evaluated.

MT1002 Phase II Study in ACS Patients With PCI

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Acute Coronary Syndrome
    Acute Coronary Syndrome
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: MT1002

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: MT1002

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Jay Traverse, Minneapolis, Minnesota, United States

Brief Summary

This is an open-label, sequential-dose escalation/de-escalation trial testing 3 dose levels of MT1002 in patients undergoing PCI due to ACS with NSTEMI.

Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Covid-19
    Covid-19
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Famotidine, Drug: Placebo

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Famotidine, Drug: Placebo

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Northwell Health, Lake Success, New York, United States

Brief Summary

The overall objective of this study is to evaluate the clinical efficacy of oral famotidine in symptomatic non-hospitalized patients with confirmed COVID-19. This study is expected to enroll up to 84 patients with mild to moderate symptoms divided into each of the two study arms. Clinical outcomes of the two treatment arms will be compared. This study will be conducted virtually/remotely.